FDA approves Ironwood’s Linzess for young children With constipation

Ironwood Pharmaceuticals (NASDAQ:IRWD) secured expanded U.S. regulatory clearance for its blockbuster drug Linzess, making it the first and only prescription medication available for young children suffering from functional constipation.

The U.S. Food and Drug Administration cleared the drug for pediatric patients aged two years and older.

Linzess was previously restricted to patients aged six and older for this specific chronic gastrointestinal condition.

This key label expansion opens up immediate availability to children between the ages of two and five, an underserved demographic that frequently experiences limited success with standard retail treatments.

Functional constipation in children is a chronic condition characterized by infrequent, hard bowel movements that are often difficult or painful to pass.

It remains a pervasive issue for parents and healthcare providers, affecting an estimated 3% of preschool-aged children worldwide.

Many young patients continue to experience persistent symptoms despite being treated with over-the-counter laxatives or dietary fiber adjustments, creating a distinct gap in commercial pediatric care.

The FDA's decision to grant priority review and subsequent approval was supported by data from a 12-week Phase 3 randomized, placebo-controlled clinical trial.

In the study, a 72-microgram daily dose of Linzess demonstrated a statistically significant improvement in the frequency of spontaneous bowel movements compared to a placebo group.

The safety profile observed in the trial was consistent with the established parameters observed in previous adult and older pediatric cohorts.